Laboratory - Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
This Medicare Advantage payment policy governs Humana reimbursement for serum testing of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) antibodies and related laboratory procedure codes for Humana Medicare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria for AQP4 and MOG Antibody Testing
Coverage criteria for AQP4 and MOG antibody testing
Humana Medicare Advantage reimbursement criteria for serum antibody testing:
ALL of the following
ONE of the following clinical indications
- Blindness or vision loss
- Demyelinating disease
- Disease of spinal cord
- Encephalitis
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.